Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -219.24% is 106% below its 5-year average of 3473.86%, near the low end of its 5-year range (-219.24%–21614.29%).
As of the fiscal period ended Tuesday, March 31, 2026. 15.97% below its 12-month average of -189.06%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
-219.24%
RETURN ON EQUITY (ROE) AVG TTM
-189.06%
RETURN ON EQUITY (ROE) AVG 3Y
-180.53%
RETURN ON EQUITY (ROE) AVG 5Y
3473.86%
RETURN ON EQUITY (ROE) AVG 10Y
1903.08%
RETURN ON EQUITY (ROE) AVG 15Y
-26.63%
RETURN ON EQUITY (ROE) AVG 20Y
14.75%
CURRENT VS TTM AVG
-15.97%
CURRENT VS 3Y AVG
-21.44%
CURRENT VS 5Y AVG
-106.31%
CURRENT VS 10Y AVG
-111.52%
CURRENT VS 15Y AVG
-723.44%
CURRENT VS 20Y AVG
-1586.16%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-2113.22%
vs the sector median at left
McKesson Corporation
Market Cap
$99.40B
Return on Equity (ROE)
-219.24%
TTM Avg
-189.06%
3Y Avg
-180.53%
5Y Avg
3473.86%
Market Cap
$110.33B
Return on Equity (ROE)
9.70%
TTM Avg
9.71%
3Y Avg
8.51%
5Y Avg
8.44%
Market Cap
$87.28B
Return on Equity (ROE)
-112.56%
TTM Avg
-171.53%
3Y Avg
-210.62%
5Y Avg
-155.29%
Market Cap
$82.07B
Return on Equity (ROE)
11.06%
TTM Avg
13.69%
3Y Avg
14.71%
5Y Avg
14.93%
Market Cap
$119.63B
Return on Equity (ROE)
22.41%
TTM Avg
8.96%
3Y Avg
15.60%
5Y Avg
19.47%
Market Cap
$78.56B
Return on Equity (ROE)
11.15%
TTM Avg
14.72%
3Y Avg
15.95%
5Y Avg
23.11%
Market Cap
$74.52B
Return on Equity (ROE)
15.05%
TTM Avg
11.32%
3Y Avg
12.19%
5Y Avg
12.83%
Market Cap
$71.98B
Return on Equity (ROE)
14.18%
TTM Avg
10.21%
3Y Avg
8.16%
5Y Avg
6.40%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| McKesson Corporation (MCK) | $99.40B | -219.24% | -189.06% | -180.53% | 3473.86% |
| GSK plc (GSK)vs › | $102.46B | 25.19% | 26.90% | 55.97% | 45.70% |
| Medtronic plc (MDT)vs › | $110.33B | 9.70% | 9.71% | 8.51% | 8.44% |
| HCA Healthcare, Inc. (HCA)vs › | $87.28B | -112.56% | -171.53% | -210.62% | -155.29% |
| Elevance Health Inc. (ELV)vs › | $82.07B | 11.06% | 13.69% | 14.71% | 14.93% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $119.63B | 22.41% | 8.96% | 15.60% | 19.47% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $78.56B | 11.15% | 14.72% | 15.95% | 23.11% |
| Cigna Corporation (CI)vs › | $74.52B | 15.05% | 11.32% | 12.19% | 12.83% |
| Boston Scientific Corporation (BSX)vs › | $71.98B | 14.18% | 10.21% | 8.16% | 6.40% |
| Stryker Corporation (SYK)vs › | $129.60B | 7.78% | 14.50% | 15.05% | 14.30% |
ROE
-219.2%
ROA
5.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-03-31 | -219.24% |
| 2025-03-31 | -158.87% |
| 2024-03-31 | -152.31% |
| 2023-03-31 | -191.71% |
| 2022-03-31 | -49.03% |
| 2021-03-31 | 21614.29% |
| 2020-03-31 | 17.67% |
| 2019-03-31 | 0.42% |
| 2018-03-31 | 0.68% |
| 2017-03-31 | 46.71% |
| 2016-03-31 | 25.30% |
| 2015-03-31 | 18.45% |
| 2014-03-31 | 14.82% |
| 2013-03-31 | 18.93% |
| 2012-03-31 | 20.54% |
| 2011-03-31 | 15.65% |
| 2010-03-31 | 16.77% |
| 2009-03-31 | 13.29% |
| 2008-03-31 | 16.17% |
| 2007-03-31 | 15.35% |
| 2006-03-31 | 12.49% |
| 2005-03-31 | -2.98% |
| 2004-03-31 | 12.52% |
| 2003-03-31 | 12.26% |
| 2002-03-31 | 10.62% |
| 2001-03-31 | -1.38% |
| 2000-03-31 | 20.30% |
| 1999-03-31 | 2.95% |
| 1998-03-31 | 11.01% |
| 1997-03-31 | 10.62% |
